Zydus-Cadila is developing ZYH-7, a PPAR alpha modulator for the potential treatment of dyslipidemia .
By January 2012, phase II trials had begun ; in January 2014, the drug was still listed as being in phase II development
By January 2012 phase II trials had begun for Diabetes type 2 Lipoprotein disorders
In August 2007, an IND was filed , and by March 2008, a phase I trial was underway ; by April 2011, the trial had been completed
Dyslipidemia is an abnormal amount of lipids (e.g. cholesterol and/or fat) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.
|Classification and external resources|
Physicians and basic researchers classify dyslipidemias in two distinct ways:
- Phenotype, or the presentation in the body (including the specific type of lipid that is increased)
- Etiology, or the reason for the condition (genetic, or secondary to another condition). This classification can be problematic, because most conditions involve the intersection of genetics and lifestyle issues. However, there are a few well-defined genetic conditions that are usually easy to identify.
|Elevated Lipoprotein||Chylomicron||LDL||LDL and VLDL||IDL||VLDL||VLDL and chylomicrons|
Scheme 1 below which comprises:
|Citing Patent||Filing date||Publication date||Applicant||Title|
|WO2009021740A2||Aug 14, 2008||Feb 19, 2009||Sanofis Aventis||Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments|
|WO2010049946A2 *||Oct 22, 2009||May 6, 2010||Cadila Healthcare Limited||Thyroid receptor ligands|
|WO2010084512A1 *||Dec 22, 2009||Jul 29, 2010||Cadila Healthcare Limited||Novel oxime derivatives|
|WO2010110479A1 *||Mar 24, 2010||Sep 30, 2010||Nippon Chemiphar Co., Ltd.||Activator for peroxisome proliferator-activated receptor|
|WO2011157827A1||Jun 17, 2011||Dec 22, 2011||Sanofi||Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases|
|WO2013037390A1||Sep 12, 2011||Mar 21, 2013||Sanofi||6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors|
|WO2014192023A1 *||May 20, 2014||Dec 4, 2014||Cadila Healthcare Limited||Novel compounds suitable for the treatment of dyslipidemia|
|EP2567959A1||Sep 12, 2011||Mar 13, 2013||Sanofi||6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors|
|US8742117||Dec 22, 2009||Jun 3, 2014||Cadila Healthcare Limited||Oxime derivatives|
|US8822414 *||Dec 26, 2011||Sep 2, 2014||Cadila Healthcare Limited||Heterocyclic compounds suitable for the treatment of dyslipidemia|